The DCAT Pulse: The Tariff Outlook & Pharma

Evolving US tariff policy is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharma companies and their suppliers. A DCAT webinar gives an executive briefing on what is crucial to consider in supply planning amid tariff uncertainty.

Evolving US tariff/trade policy is top of mind for the bio/pharma industry and is a key variable in the cost structures, manufacturing strategies, and supply chains of bio/pharmaceutical companies and their suppliers. Unpacking what tariffs are in place, and what additional tariffs may come to be and how they will be implemented is a challenge unto itself, but an even greater challenge is how can companies put forth effective supply plans amid such tariff uncertainty?

To address that critical question, a DCAT webinar, The Tariff Outlook & Pharma, airing January 22, 2026 (10:00-10:30 AM EST-US), brings together leading industry experts on what may lie ahead in 2026 and what is important to consider in effective supply planning. Jens Charlieson, Head of Transport & Trade Compliance at Swedish Orphan Biovitrum AB (Sobi), and Gabriela de Almeida, Managing Director and Partner at Boston Consulting Group, will share key insights on the crucial factors and scenarios to consider for effective supply planning and trade compliance.

The webinar is part of The DCAT Pulse, a new, member-focused insights hub from the Drug, Chemical & Associated Technologies Association (DCAT) that brings together fresh perspectives and seasoned expertise, spotlighting trends and opportunities that help DCAT Member Companies stay informed, engaged, and ahead of the curve in a dynamic marketplace.

The webinar, The Tariff Outlook & Pharma, was developed by the volunteer DCAT Supply Management Committee, composed of senior to mid-level executives involved in sourcing, procurement and supply management. The webinar is provided exclusively and complimentary to all employees of DCAT Member Companies, who can register here. Not able to attend the webinar on January 22? No problem. The webinar will be available for on-demand viewing, but you must register to view.

Recent Feature Articles

The Making of a Molecule: Peptide Synthesis 

By
The success of the GLP-1 agonists and related follow-on drugs has renewed interest in peptide-based drugs. Industry experts share their perspectives on the latest in peptide synthesis. 

FDA Launches 1-Day Inspections Pilot

By
As part of a broader initiative to make its inspectional resources efficient, FDA has launched a pilot for one-day inspectional assessments. What does the new program involve?

Manufacturing Insights: Novartis’ Next Move

By
Novartis announced this week another leg in its $23-billion US capital investment plan—a new API manufacturing facility in North Carolina. Is the company’s manufacturing strategy aligning with its overall growth strategy?

Finding a Niche: Rare-Disease Drugs & Deal-Making

By
Are rare-disease drugs still factoring into the growth strategies of the pharmaceutical majors? Which recent deals stand out? DCAT Value Chain Insights takes an inside look at the companies, products, and deals.